<DOC>
	<DOCNO>NCT00289718</DOCNO>
	<brief_summary>The aim study evaluate long-term persistence hepatitis A B antibodies Years 11 , 12 , 13 , 14 15 year subject receive first dose 3 dose vaccination schedule combine hepatitis A/hepatitis B vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . This protocol post deal objective &amp; outcome measure extension phase year 11 15 .</brief_summary>
	<brief_title>Long-Term Immune Persistence GSK Biologicals ' Combined Hepatitis A &amp; B Vaccine Injected According 0,1,6 Month Schedule</brief_title>
	<detailed_description>This long-term follow-up study Years 11 , 12 , 13 , 14 15 primary vaccination GSK Biologicals ' hepatitis A/hepatitis B vaccine ( three-dose schedule , 3 different lot ) . To evaluate long-term antibody persistence , volunteer bleed Years 11 , 12 , 13 , 14 15 first vaccine dose primary vaccination course determine anti-HAV anti-HBs antibody concentration . No additional subject recruit course long-term study . If subject become seronegative anti-HAV antibody lose anti-HBs seroprotection concentration long-term blood sampling time point ( i.e . Years 11 , 12 , 13 , 14 15 ) , he/ offer additional vaccine dose .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects participate study receive threedose primary vaccination combine hepatitis A/hepatitis B vaccine primary study . Written inform consent obtain subject blood sample visit year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Combined Hepatitis A B vaccine</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>